Precision for Medicine is a global clinical research organization (CRO) founded in 2012 and headquartered in Frederick, Maryland, United States. It specializes in providing biomarker-driven clinical research and development services to the life sciences sector, particularly focusing on oncology, rare diseases, and autoimmune conditions. The company integrates clinical trial excellence, laboratory expertise, and advanced data sciences to maximize insights into patient biology and accelerate clinical development and approval of therapies.

The organization offers a comprehensive portfolio of services encompassing biospecimens, central lab services, flow cytometry, immune monitoring, advanced tissue and liquid biopsy profiling, bioanalysis of large molecules and biologics, genomics, histopathology, cytokine analysis, proteomics, target and biomarker validation, and regulatory consulting for in vitro diagnostics and companion diagnostics. This integration supports clinical trials at all stages from early development through approval.

Precision for Medicine also provides global clinical trial management including design, biostatistics, data management, study startup, feasibility, and patient recruitment. It extends its capabilities with manufacturing strategy and execution through its Project Farma initiative, enhanced by acquiring Baseline Controls to expand end-to-end manufacturing solutions for life science companies.

As part of the Precision Medicine Group, Precision for Medicine has a presence across 40 global locations in North America, Europe, and Asia-Pacific, employing over 3,400 people. The company is recognized for driving a transformational approach that merges clinical operations, laboratory expertise, and data intelligence to deliver faster, more precise patient-targeted treatments worldwide.